Novus Biologicals Adds Cdx1 to Antibody Catalog

Novus Biologicals recently announced a new rabbit polyclonal anti-Cdx1 antibody (catalog number NBP1-49538).  This Cdx1 antibody was developed using SDIX's Genomic Antibody TechnologyTM (GATTM) and Cdx1 antibodies are applicable for chromatin and epigenetics research.

Novus' new Cdx1 antibody was quality controlled by immunohistochemical analysis in mouse skin and by immunocytochemical analysis in HeLa cells. This polyclonal Cdx1 antibody reacts with human and mouse.

Caudal-type homeobox protein 1 (CDX1) and its relative Caudal-type homeobox protein 2 (CDX2) are transcription factors that are members of the caudal-related homeobox gene family.  Both Cdx1 and Cdx2 are important in controlling epithelial cell differentiation, proliferation, and function in the intestine.

Novus' new anti-Cdx-1 antibody was developed in conjunction with SDIX using their Genomic Antibody TechnologyTM.  GAT uses sophisticated bioinformatics and immunization strategies to produce high-quality antibodies that specifically bind to that region of the protein in its naturally folded form. The ability of any antibody to recognize a protein’s naturally folded state has the potential to expand an antibody’s utility to high-value applications like sandwich immunoassay, ChIP, and flow cytometry.  Learn more about GAT by reading the GAT White Paper or by viewing GAT FAQs on the Novus website.

About Novus Biologicals (

Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science.  Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community.  All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet.  By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.

About SDIX (

SDIX is a biotechnology company delivering advanced immuno-solutions and critical reagents to the life science sector, including pharmaceutical, biotechnology, diagnostic, and basic research partners as well as effective pathogen detection tests to help ensure food safety.  In life science, SDIX helps scientists discover the mechanisms of disease, facilitate the development of new drugs, and provide tools for rapid diagnosis through its suite of fully integrated immuno-solutions  â€“ from targeted antigen design to create unique antibodies, to assay design, development, and production. In food safety, SDIX rapid assays help customers reduce time, labor, and costs while increasing accuracy and reliability of food pathogen detection.

This news release may contain forward-looking statements reflecting SDIX's current expectations.

When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.


Release Date: 
Wednesday, December 29, 2010 - 07:00